Comparison of recurrence rate and risk factors in patients with focal adenomyosis with and without medical treatment after conservative surgery
article
OA: closed
CC0
⤵ 3 in-corpus citations
AI-generated summary
Postoperative medical treatment with GnRH agonists or LNG-IUS significantly reduced recurrence rates in focal adenomyosis patients after conservative surgery.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
OBJECTIVE: To compare the recurrence rate and risk factors between conservative surgery followed by medical treatments and conservative surgery-only in patients with focal adenomyosis.
METHODS: This retrospective study was conducted in a single teaching hospital from May 2011 to October 2016. All eligible patients were identified into three groups: surgery-only group, surgery combined with gonadotropin-releasing hormone agonist (GnRHa), and a levonorgestrel-releasing intrauterine system (LNG-IUS) group. The recurrence rate and risk factors were compared among groups using Kaplan-Meier and Cox proportional hazards analyses. Receiver operating characteristic (ROC) curve analysis was applied to determine a cut-off value for identifying recurrence-related risk factors.
RESULTS: A total of 249 postoperative patients with adenomyosis were included in the final analysis with a mean of 41 months of follow up. The recurrence rate at the long-term follow up was significantly lower in intervention groups than in the surgery-only group (P = 0.011). The Cox proportional hazards and ROC analyses showed that a menstrual cycle longer than 26 days (P = 0.026), diameter of lesions <6 cm (P = 0.030), and combination treatment using GnRHa (P = 0.039) or LNG-IUS (P = 0.007) were protective against relapse. The risk of recurrence was lower in patients with anterior (P = 0.034) or fundus (P = 0.038) adenomyosis.
CONCLUSION: Postoperative therapy using GnRHa or LNG-IUS decreases the long-term relapse rate in women undergoing conservative surgery.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (23)
- Abnormal uterine bleeding via openalex
- Conservative surgical treatment of adenomyosis to improve fertility: Controversial values, indications, complications, and pregnancy outcomes via openalex
- Evaluation of Serum CA 125 Levels in Patients with Pelvic Pain Related to Endometriosis via openalex
- Exploring the challenges for a new classification of adenomyosis via openalex
- Factors affecting the spontaneous expulsion of the levonorgestrel-releasing intrauterine system via openalex
- Fertility outcome of infertile women with adenomyosis treated with the combination of a conservative microsurgical technique and GnRH agonist: Long-term follow-up in a series of nine patients via openalex
- Is it time for a paradigm shift in drug research and development in endometriosis/adenomyosis? via openalex
- Length of Menstrual Cycle and Risk of Endometriosis via openalex
- Postoperative maintenance levonorgestrel-releasing intrauterine system for symptomatic uterine adenomyoma via openalex
- Pregnancy after medical therapy of adenomyosis with a gonadotropin-releasing hormone agonist via openalex
- Surgical and medical treatment of adenomyosis via openalex
- Uterine adenomyosis and adenomyoma: the surgical approach via openalex
- W6818121131 via openalex
- W2042677510 via openalex
- W2065386825 via openalex
- W2081898822 via openalex
- W2163445615 via openalex
- W2736858912 via openalex
- W2781620608 via openalex
- W2873462695 via openalex
- W2890798448 via openalex
- W6811854414 via openalex
- W2019524523 via openalex
Cited by (3)
- Alternative treatments of adenomyosis - an update in procedural management and clinical outcomes 2024
- Both adjuvant and maintenance therapies are needed in women with symptomatic adenomyosis after uterus-sparing treatment 2023
- Letter to the editor: Adjuvant or maintenance therapy may be needed in adenomyosis patients after uterus-sparing surgery 2023
Source provenance
- europepmc
- last seen: 2026-06-14T06:08:20.186862+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-06-14T06:07:51.997929+00:00
License: CC0
· commercial use OK